Abstract
Background: Hyperglycemia in pregnancy, which can adversely affect both maternal and fetal outcomes. Sustainable strategies for its management are urgently needed. This study explores the therapeutic efficacy of Lactococcus lactis D4 (LD4), a probiotic strain isolated from traditional fermented buffalo milk (dadiah), as an innovative biofunctional approach to controlling hyperglycemia. Methods: This experimental study involved 20 pregnant mice divided into four groups: K1 (control), K2 (10% glucose induction), K3 (10% glucose induction plus metformin) and K4 (10% glucose induction plus LD4). Blood glucose levels were measured at baseline. Laparotomy was performed on day 16 to assess maternal body weight, fetal number and fetal body weight. Data were analyzed using repeated-measures ANOVA followed by Duncan’s Multiple Range Test, with statistical significance set at p less than 0.05. Results LD4 administration during pregnancy did not affect maternal body weight, fetal count, or fetal body weight (p greater than 0.05). However, LD4 significantly influenced blood glucose levels in mice (p less than 0.05). LD4 demonstrates significant effects, indicating its potential as a probiotic-based strategy for managing hyperglycemia during pregnancy. Further studies are needed to confirm its long-term safety and efficacy in clinical settings.in improving glycemic control during pregnancy and shows strong potential to become an effective probiotic.